Transgene Past Earnings Performance
Past criteria checks 0/6
Transgene's earnings have been declining at an average annual rate of -37.8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 2.3% per year.
Key information
-37.8%
Earnings growth rate
-35.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 2.3% |
| Return on equity | -143.0% |
| Net Margin | -282.6% |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Transgene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 8 | -22 | 7 | 0 |
| 30 Sep 23 | 8 | -28 | 7 | 0 |
| 30 Jun 23 | 9 | -33 | 7 | 0 |
| 31 Mar 23 | 10 | -33 | 8 | 0 |
| 31 Dec 22 | 10 | -33 | 8 | 0 |
| 30 Sep 22 | 14 | -28 | 8 | 0 |
| 30 Jun 22 | 18 | -23 | 8 | 0 |
| 31 Mar 22 | 18 | -21 | 8 | 0 |
| 31 Dec 21 | 17 | -20 | 7 | 0 |
| 30 Sep 21 | 13 | -23 | 7 | 0 |
| 30 Jun 21 | 9 | -27 | 6 | 0 |
| 31 Mar 21 | 9 | -22 | 6 | 0 |
| 31 Dec 20 | 10 | -17 | 7 | 0 |
| 30 Sep 20 | 12 | -11 | 7 | 0 |
| 30 Jun 20 | 14 | -6 | 7 | 0 |
| 31 Mar 20 | 14 | -12 | 7 | 0 |
| 31 Dec 19 | 13 | -19 | 7 | 0 |
| 30 Sep 19 | 11 | -6 | 7 | 0 |
| 30 Jun 19 | 8 | 8 | 8 | 0 |
| 31 Mar 19 | 8 | 8 | 7 | 0 |
| 31 Dec 18 | 7 | 8 | 7 | 0 |
| 30 Sep 18 | 7 | -10 | 6 | 4 |
| 30 Jun 18 | 7 | -29 | 6 | 9 |
| 31 Mar 18 | 7 | -31 | 6 | 15 |
| 31 Dec 17 | 7 | -32 | 6 | 22 |
| 30 Sep 17 | 8 | -32 | 6 | 22 |
| 30 Jun 17 | 9 | -31 | 6 | 22 |
| 31 Mar 17 | 9 | -28 | 6 | 20 |
| 31 Dec 16 | 10 | -24 | 6 | 18 |
| 30 Sep 16 | 10 | -26 | 6 | 19 |
| 30 Jun 16 | 9 | -28 | 6 | 20 |
| 31 Mar 16 | 9 | -33 | 6 | 22 |
| 31 Dec 15 | 10 | -38 | 6 | 24 |
| 30 Sep 15 | 10 | -40 | 6 | 25 |
| 30 Jun 15 | 10 | -42 | 7 | 26 |
| 31 Mar 15 | 11 | -41 | 7 | 26 |
| 31 Dec 14 | 11 | -41 | 8 | 27 |
| 30 Sep 14 | 13 | -41 | 7 | 28 |
| 30 Jun 14 | 15 | -41 | 7 | 30 |
| 31 Mar 14 | 15 | -42 | 7 | 32 |
| 31 Dec 13 | 16 | -43 | 7 | 34 |
| 30 Sep 13 | 15 | -44 | 7 | 34 |
| 30 Jun 13 | 14 | -45 | 7 | 34 |
Quality Earnings: TGNA is currently unprofitable.
Growing Profit Margin: TGNA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TGNA is unprofitable, and losses have increased over the past 5 years at a rate of 37.8% per year.
Accelerating Growth: Unable to compare TGNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TGNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: TGNA has a negative Return on Equity (-143.02%), as it is currently unprofitable.